# ELEVATE-HFpEF Clinical Study

Study · id `cardio:ct-nct06678841` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06678841](<https://clinicaltrials.gov/study/NCT06678841>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06678841

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 700 participants.

## Technical summary

Registry record NCT06678841. Randomized; double masking; primary purpose treatment. Start 2025-07-09 (actual); primary completion 2028-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT06678841, source copy `cardio:ctgov-nct06678841-2026-11-03`, retrieved 2026-11-18)
- Started: 2025-07-09 (actual) (ClinicalTrials.gov record NCT06678841, source copy `cardio:ctgov-nct06678841-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2028-08 (anticipated) (ClinicalTrials.gov record NCT06678841, source copy `cardio:ctgov-nct06678841-2026-11-03`, retrieved 2026-11-18)
- Completion: 2029-02 (anticipated) (ClinicalTrials.gov record NCT06678841, source copy `cardio:ctgov-nct06678841-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Australia; Austria; Belgium; Canada; Czechia; France; Germany; Hong Kong SAR China; Japan; Malaysia; Norway; Slovenia; Switzerland; United Kingdom (ClinicalTrials.gov record NCT06678841, source copy `cardio:ctgov-nct06678841-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06678841-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: ELEVATE-HFpEF Clinical Study
- Acronym: ELEVATE-HFpEF
- Condition: Heart Failure With Preserved Ejection Fraction (HFpEF)
- Intervention (Device): Personalized cardiac pacing
- Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: Medtronic Cardiac Rhythm and Heart Failure (`cardio:org-medtronic-cardiac-rhythm-and-heart-failure`)

## Provenance

Content hash: 6e61466e9c549eedeb90f2d847b638f51e2aeea07039b1b8f0f8f51a05afeb7a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
